Indivior PLC
INDV.LIndivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market.
Drugs in Pipeline
16
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
SUBOXONE
Opioid Dependence
RBP-7000
Schizophrenia
SUBOXONE sublingual film
Opioid Use Disorder
RBP-6000
Opioid Use Disorder
INDV-2000
Opioid Use Disorder
RBP-8000 100 mg
Opioid Dependence
RBP-6300
Opioid Related Disorder
Buprenorphine hydrochloride marketed sublingual tablet (Subutex)
Opioid Dependency
Buprenorphine/naloxone Film Strip
Opioid-Related Disorders
Arbaclofen Placarbil
Alcohol Use Disorder
Risperidone
Schizophrenia
Subutex
Opioid Related Disorder
Buprenorphine soluble film
Opioid-related Disorders
XP19986 CR
GERD
Buprenorphine
Opioid Use Disorder
INDV-6001
Moderate to Severe Opioid Use Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SUBOXONE | Phase 3 | Opioid Dependence | - | - |
RBP-7000 | Phase 3 | Schizophrenia | - | - |
SUBOXONE sublingual film | Phase 3 | Opioid Use Disorder | - | - |
RBP-6000 | Phase 3 | Opioid Use Disorder | - | - |
INDV-2000 | Phase 2 | Opioid Use Disorder | - | - |
RBP-8000 100 mg | Phase 2 | Opioid Dependence | - | - |
RBP-6300 | Phase 2 | Opioid Related Disorder | - | - |
Buprenorphine hydrochloride marketed sublingual tablet (Subutex) | Phase 2 | Opioid Dependency | - | - |
Buprenorphine/naloxone Film Strip | Phase 2 | Opioid-Related Disorders | - | - |
Arbaclofen Placarbil | Phase 2 | Alcohol Use Disorder | - | - |
Risperidone | Phase 2 | Schizophrenia | - | - |
Subutex | Phase 2 | Opioid Related Disorder | - | - |
Buprenorphine soluble film | Phase 2 | Opioid-related Disorders | - | - |
XP19986 CR | Phase 2 | GERD | - | - |
Buprenorphine | Phase 2 | Opioid Use Disorder | - | - |
INDV-6001 | Phase 2 | Moderate to Severe Opioid Use Disorder | - | - |